Tyra Biosciences, Inc. (TYRA): Shareholders' Equity
$259.18M
As of 2025-12-31
$353.66M
As of 2026-06-30
+0.2%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $259.18M | -24.5% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $343.15M | +68.0% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $204.26M | -20.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $257.83M | -14.6% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $301.74M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | -$13.64M | n/a | 2022-03-03, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $259.18M | -24.5% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $154.66M | +289.9% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $89.83M | +47.9% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $224.89M | +82.1% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $211.65M | -27.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $245.15M | +75.7% |
| Neurogene Inc. (NGNE) | 2025-12-31 | $264.89M | -14.7% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $260.99M | +31.8% |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗